|
122 Companies |
|
195 Products |
|
195 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2333 News |
|
| «12...2627282930313233343536...4647» |
- |||| PBT2 / Alterity Therap
Trial completion: Reach2HD: Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease (clinicaltrials.gov) - Feb 8, 2014
P2, N=109, Completed, Sponsor: Prana Biotechnology Limited
Active, not recruiting --> Completed
- Enrollment open: Study of the Effect of the Cognitive Orientation to Daily Occupational Performance (CO-OP) on Cognitive Impairment in Parkinson's Disease (clinicaltrials.gov) - Feb 7, 2014
P=N/A, N=6, Recruiting, Sponsor: University of Manitoba
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Enrollment closed: ARTEMIDA: Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) (clinicaltrials.gov) - Feb 4, 2014
P3, N=500, Active, not recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: CONNECT: Testing the Effectiveness of Telephone Support for Dementia Caregivers (clinicaltrials.gov) - Feb 4, 2014
P=N/A, N=154, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- quetiapine / Generic mfg.
New P1/2 trial: Efficacy of Quetiapine for Pediatric Delirium (clinicaltrials.gov) - Feb 3, 2014
P1/2, N=50, Recruiting, Sponsor: Weill Medical College of Cornell University
- ||||||| donepezil / Generic mfg.
Trial completion: A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase (clinicaltrials.gov) - Jan 30, 2014
P3, N=142, Completed, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P4 trial: Evaluation of Reader Training Processes (clinicaltrials.gov) - Jan 29, 2014
P4, N=250, Recruiting, Sponsor: Avid Radiopharmaceuticals
- | Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
New P1 trial, Combination therapy: Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults (clinicaltrials.gov) - Jan 29, 2014
P1, N=28, Active, not recruiting, Sponsor: Takeda
- modafinil / Generic mfg.
Trial initiation date: Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil (clinicaltrials.gov) - Jan 28, 2014
P4, N=48, Recruiting, Sponsor: Mount Sinai School of Medicine
Active, not recruiting --> Completed Initiation date: Sep 2013 --> Jan 2014
- modafinil / Generic mfg.
Enrollment open: Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil (clinicaltrials.gov) - Jan 28, 2014
P4, N=48, Recruiting, Sponsor: Mount Sinai School of Medicine
Initiation date: Sep 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- ||| vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Enrollment change: A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Jan 28, 2014
P2a, N=111, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=160 --> 111
- | ketamine / Generic mfg.
New P2 trial, Surgery: SPMSQ-E: Ketamine and Changes of the Short Portable Mental Status Questionnaire (clinicaltrials.gov) - Jan 28, 2014
P2, N=80, Completed, Sponsor: Instituto Mexicano del Seguro Social
- |||| vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Trial completion: A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Jan 28, 2014
P2a, N=111, Completed, Sponsor: Pfizer
N=160 --> 111 Active, not recruiting --> Completed
- ||||| rivastigmine transdermal / Generic mfg.
Enrollment change: Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) (clinicaltrials.gov) - Jan 27, 2014
P3, N=101, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=79 --> 101
- ketamine / Generic mfg.
Trial completion, Surgery: SPMSQ-E: Ketamine and Changes of the Short Portable Mental Status Questionnaire (clinicaltrials.gov) - Jan 27, 2014
P2, N=80, Completed, Sponsor: Instituto Mexicano del Seguro Social
N=79 --> 101 Not yet recruiting --> Completed
- | rivastigmine transdermal / Generic mfg.
Trial initiation date: The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems (clinicaltrials.gov) - Jan 23, 2014
P4, N=15, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Completed Initiation date: Nov 2009 --> Apr 2010
- Enrollment open: German Adaptation of REACH II (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=158, Recruiting, Sponsor: University of Leipzig
Initiation date: Nov 2009 --> Apr 2010 Not yet recruiting --> Recruiting
- dronabinol oral / Generic mfg.
Trial completion: Delta-THC in Behavioral Disturbances in Dementia (clinicaltrials.gov) - Jan 20, 2014
P2, N=22, Completed, Sponsor: Radboud University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Biomarker, Trial completion: Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=41, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
New P1 trial: AZD3293TQT: AZD3293 Thorough QT Study in Healthy Male Volunteers (clinicaltrials.gov) - Jan 16, 2014
P1, N=52, Active, not recruiting, Sponsor: AstraZeneca
- |||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Enrollment open: STARBEAM: Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (clinicaltrials.gov) - Jan 16, 2014
P3, N=840, Recruiting, Sponsor: H. Lundbeck A/S
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- midazolam hydrochloride / Generic mfg.
Enrollment open: Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Cognitive Function (clinicaltrials.gov) - Jan 14, 2014
P=N/A, N=250, Recruiting, Sponsor: Palle Toft
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Pilot Study of the Living With Hope Program for Family Caregivers of Persons With Dementia Residing in Long Term Care (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Alberta
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
New P3 trial: Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease (clinicaltrials.gov) - Jan 12, 2014
P3, N=50, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
- ||||| Nuplazid (pimavanserin) / Acadia Pharma
New P2 trial: A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (clinicaltrials.gov) - Jan 12, 2014
P2, N=212, Recruiting, Sponsor: ACADIA Pharmaceuticals Inc.
- || PF-05236812 / J&J, Pfizer
Enrollment closed: Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Jan 11, 2014
P1, N=104, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- atabecestat (JNJ-54861911) / J&J
Enrollment open: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Jan 9, 2014
P1, N=24, Recruiting, Sponsor: Janssen Research & Development, LLC
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| EVP-0962 / Forum Pharmaceuticals
Trial completion: Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease (clinicaltrials.gov) - Jan 9, 2014
P2, N=52, Completed, Sponsor: EnVivo Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Efficacy of Early Stage Alzheimer's Support Groups (clinicaltrials.gov) - Jan 8, 2014
P=N/A, N=154, Completed, Sponsor: University of Washington
Recruiting --> Completed Active, not recruiting --> Completed
- | AADvac1 / Axon Neurosci
New P1 trial: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - Jan 7, 2014
P1, N=30, Not yet recruiting, Sponsor: Axon Neuroscience SE
- modafinil / Generic mfg.
New P3 trial: Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill (clinicaltrials.gov) - Jan 5, 2014
P3, N=30, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- ||| vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Enrollment change: Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - Jan 5, 2014
P2a, N=53, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed N=67 --> 53
- Trial completion: Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs. (clinicaltrials.gov) - Jan 5, 2014
P1, N=6, Completed, Sponsor: Molecular NeuroImaging
N=67 --> 53 Recruiting --> Completed
- |||| vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Trial completion: Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - Jan 5, 2014
P2a, N=53, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- Targretin oral (bexarotene oral) / ReXceptor
Enrollment closed: BEAT-AD: Bexarotene Amyloid Treatment for Alzheimer's Disease (clinicaltrials.gov) - Dec 26, 2013
P2, N=20, Active, not recruiting, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- zolpidem ER / Generic mfg.
Clinical data, Enrollment change: Zolpidem CR and Hospitalized Patients With Dementia (clinicaltrials.gov) - Dec 18, 2013
P=N/A, N=17, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting N=24 --> 17
- || Nivadil (nilvadipine) / Cortice Biosci
New P3 trial, P3 data: A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease (clinicaltrials.gov) - Dec 18, 2013
P3, N=500, Recruiting, Sponsor: Prof Brian Lawlor
- zolpidem ER / Generic mfg.
Clinical data, Trial completion: Zolpidem CR and Hospitalized Patients With Dementia (clinicaltrials.gov) - Dec 18, 2013
P=N/A, N=17, Completed, Sponsor: Massachusetts General Hospital
N=24 --> 17 Recruiting --> Completed
- Enrollment change: GMS-Package: Validation of the French Version of the Geriatric Mental State (GMS) (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=96, Completed, Sponsor: University Hospital, Tours
Recruiting --> Completed N=120 --> 96
- Trial completion: GMS-Package: Validation of the French Version of the Geriatric Mental State (GMS) (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=96, Completed, Sponsor: University Hospital, Tours
N=120 --> 96 Recruiting --> Completed
- Dojolvi (triheptanoin) / Ultragenyx
Trial completion: Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease (clinicaltrials.gov) - Dec 16, 2013
P2, N=10, Completed, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Recruiting --> Completed Recruiting --> Completed
- Egrifta (tesamorelin acetate) / Theratechnologies, Massachusetts General Hospital
Trial completion: SMART: Somatotrophics, Memory, and Aging Research Trial (clinicaltrials.gov) - Dec 16, 2013
P2, N=151, Completed, Sponsor: University of Washington
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=50, Recruiting, Sponsor: Winthrop University Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: ICTUS: Transient Global Amnesia (TGA). Exploratory Study of the Default Mode Network During the Acute Phase (clinicaltrials.gov) - Dec 11, 2013
P=N/A, N=44, Not yet recruiting, Sponsor: University Hospital, Toulouse
- Enrollment open: The Cognitive and Cardiovascular Health in the Elderly Study (clinicaltrials.gov) - Dec 11, 2013
P=N/A, N=386, Recruiting, Sponsor: University Hospital, Limoges
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Affitope AD02 / AFFiRiS
Trial termination: Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=11, Terminated, Sponsor: Affiris AG
Not yet recruiting --> Recruiting Enrolling by invitation --> Terminated; The Study could not be done for every potential participant as planned in the protocol for organizational reasons.
- Affitope AD02 / AFFiRiS
Enrollment change: Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=11, Terminated, Sponsor: Affiris AG
Enrolling by invitation --> Terminated; The Study could not be done for every potential participant as planned in the protocol for organizational reasons. N=20 --> 11
- |||||| New P2b trial: Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006 (clinicaltrials.gov) - Dec 9, 2013
P2b, N=250, Enrolling by invitation, Sponsor: Affiris AG
- |||| Affitope AD02 / AFFiRiS
Trial completion, IO biomarker: Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease (clinicaltrials.gov) - Dec 9, 2013
P2, N=335, Completed, Sponsor: Affiris AG
N=20 --> 11 Active, not recruiting --> Completed
- Enrollment change: Blood-brain Barrier Permeability in Alzheimer's Disease (clinicaltrials.gov) - Dec 8, 2013
P=N/A, N=39, Completed, Sponsor: Maastricht University Medical Center
Active, not recruiting --> Completed N=60 --> 39